«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2025 01

Page:

102-108

Research Field:

Publishing date:

Info

Title:

Exploring CD164:From disease marker to new therapeutic strategies

Author(s):

WU Wei¹; WEI Jinfeng¹; XU Hui²; Abdulaziz²; SUN Xun²; CHEN Tianhao²; QIU Hongbin¹

1.School of Public Health£¬Jiamusi University,Heilongjiang Jiamusi 154007,China;2.School of Basic Medical Sciences,Jiamusi University,Heilongjiang Jiamusi 154007,China.

Keywords:

CD164; tumours; immune system diseases; zoonoses; new target

PACS:

R730

DOI:

10.3969/j.issn.1672-4992.2025.01.017

Abstract:

In recent years,numerous animal experiments and clinical studies have demonstrated abnormal expression of CD164 in various diseases.This article systematically reviews the latest research findings and discovers that CD164 exhibits unique expression patterns in different diseases,particularly playing a critical role in tumors,immune system disorders,zoonotic diseases,and many other illnesses.An in-depth analysis of these studies reveals that CD164 is not only closely associated with the occurrence and development of various diseases but also has the potential to become a new target for future disease diagnosis and treatment.Further exploration of the function and regulatory mechanism of CD164 will hopefully provide new ideas and methods for early diagnosis and precise treatment of diseases,which will in turn promote its application in clinical practice and bring greater benefits to patients' health.

References:

£Û1£Ý BRAY F,LAVERSANNE M,SUNG H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries £ÛJ£Ý.CA:A Cancer Journal for Clinicians,2024,74(3):229-263.
£Û2£Ý ºÎ˼âù,ÀîºÕ,²Üïï,µÈ.È«Çò¼°ÎÒ¹úÅ®ÐÔÈéÏÙ°©¼²²¡¸ºµ£ÄêÁä·Ö²¼¼°±ä»¯Ç÷ÊÆ£ÛJ£Ý.ÖйúÖ×ÁöÔÓÖ¾,2023,32(1):1-7. HE SY,LI H,CAO MM,et al.Age distribution and trends in the burden of disease of breast cancer in women globally and in China £ÛJ£Ý.Chinese Journal of Oncology,2023,32(1):1-7.
£Û3£Ý FENG L,HUANG S,AN G,et al.Identification of new cancer stem cell markers and signaling pathways in HER-2-positive breast cancer by transcriptome sequencing £ÛJ£Ý.International Journal of Oncology,2019,55(5):1003-1018.
£Û4£Ý VIRTANEN S,SCHULTE R,STINGL J,et al.High-throughput surface marker screen on primary human breast tissues reveals further cellular heterogeneity £ÛJ£Ý.Breast Cancer Research,2021,23:1-12.
£Û5£Ý MANCARELLA C,CALDONI G,RIBOLSI I,et al.Insulin-like growth factor 2 mRNA-binding protein 3 modulates the aggressiveness of Ewing sarcoma by regulating the CD164-CXCR4 axis £ÛJ£Ý.Frontiers in Oncology,2020,10:994-1013.
£Û6£Ý WANG CC,HUENG DY,HUANG AF,et al.CD164 regulates the proliferation,progression,and invasion of human glioblastoma cells £ÛJ£Ý.Oncotarget,2019,10(21):2041-2054.
£Û7£Ý MUKOHARA T,OZAKI Y,KITANO S,et al.Abstract P5-02-42:soluble CD163 may be a predictive biomarker of the efficacy of nivolumab plus chemotherapy in patients with HER2-negative metastatic breast cancer (WJOG9917BTR) £ÛJ£Ý.Cancer Research,2023,83(5_Supplement):P5-02-42-P5-02-42.
£Û8£Ý ºÕ½Ý,ÎâÒ»Áú,¸ßÊ÷¸ý,µÈ.Ô­·¢ÐԷΰ©ÕïÁÆÖ¸ÄÏ(2022 Äê°æ)£ÛJ£Ý.ÖйúºÏÀíÓÃҩ̽Ë÷,2022,19(9):1-28. HE J,WU YL,GAO SG,et al.Primary lung cancer treatment guidelines (2022 edition)£ÛJ£Ý.Exploring Rational Drug Use in China,2022,19(9):1-28.
£Û9£Ý CHEN WL,HHUANG AF,HUNG SM,et al.CD164 promotes lung tumor-initiating cells with stem cell activity and determines tumor growth and drug resistance via Akt/mTOR signaling £ÛJ£Ý.Oncotarget,2017,8(33):54115-54129.
£Û10£Ý LIN J,XU K,WEI J,et al.MicroRNA-124 suppresses tumor cell proliferation and invasion by targeting CD164 signaling pathway in non-small cell lung cancer £ÛJ£Ý.Journal of Gene Therapy,2016,2(1):12-23.
£Û11£Ý WEI T,CHUNG S,FU XN,et al.miR-219a-5p enhances the radiosensitivity of non-small cell lung cancer cells through targeting CD164£ÛJ£Ý.Bioscience Reports,2020,40(7):BSR20192795- BSR20192810.
£Û12£Ý ZHANG XG,ZHANG T,LI CY,et al.CD164 promotes tumor progression and predicts the poor prognosis of bladder cancer £ÛJ£Ý.Cancer Medicine,2018,7(8):3763-3772.
£Û13£Ý HAN Z,TIAN Y,LIU Q,et al.LncRNA PTAR activates the progression of bladder cancer by modulating miR-299-3p/CD164 axis £ÛJ£Ý.Pathology-Research and Practice,2022,237:153994-154005.
£Û14£Ý HUANG AF,CHEN MW,HUANG SM,et al.CD164 regulates the tumorigenesis of ovarian surface epithelial cells through the SDF-1¦Á/CXCR4 axis £ÛJ£Ý.Molecular Cancer,2013,12:1-13.
£Û15£ÝCHOI KU,KIM A,KIM JY,et al.Differences in immune-related gene expressions and tumor-infiltrating lymphocytes according to chemotherapeutic response in ovarian high-grade serous carcinoma £ÛJ£Ý.Journal of Ovarian Research,2020,13:1-11.
£Û16£Ý ZHANG XW,LI SL,ZHANG D,et al.RP11-619L19.2 promotes colon cancer development by regulating the miR-1271-5p/CD164 axis £ÛJ£Ý.Oncology Reports,2020,44(6):2419-2428.
£Û17£Ý TANG J,ZHANG L,SHE X,et al.Inhibiting CD164 expression in colon cancer cell line HCT116 leads to reduced cancer cell proliferation,mobility,and metastasis in vitro and in vivo £ÛJ£Ý.Cancer Investigation,2012,30(5):380-389.
£Û18£Ý ºÕ½Ý,³ÂÍòÇà,ÀîÄÞ,µÈ.ÖйúÇ°ÁÐÏÙ°©É¸²éÓëÔçÕïÔçÖÎÖ¸ÄÏ(2022,±±¾©)£ÛJ£Ý.ÖйúÖ×ÁöÔÓÖ¾,2022,44(1):29-53. HE J,CHEN WQ,LI N,et al.Chinese guidelines for prostate cancer screening and early diagnosis and treatment (2022,Beijing)£ÛJ£Ý.Chinese Journal of Oncology,2022,44(1):29-53.
£Û19£Ý HAVENS A,JUNG Y,SUN YX,et al.The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis £ÛJ£Ý.BMC Cancer,2006,6:1-13.
£Û20£Ý DERLIN T,RIETHDORF S,SCHUMACHER U,et al.PSMA-heterogeneity in metastatic castration-resistant prostate cancer:Circulating tumor cells,metastatic tumor burden,and response to targeted radioligand therapy £ÛJ£Ý.The Prostate,2023,83(11):1076-1188.
£Û21£Ý TU M,CAI L,ZHENG W,et al.CD164 regulates proliferation and apoptosis by targeting PTEN in human glioma £ÛJ£Ý.Molecular Medicine Reports,2017,15(4):1713-1721.
£Û22£ÝWYSOCKA M,KOSSENKOV AV,BENOIT BM,et al.CD164 and FCRL3 are highly expressed on CD4+ CD26- T cells in Sezary syndrome patients £ÛJ£Ý.Journal of Investigative Dermatology,2014,134(1):229-236.
£Û23£Ý GUENOVA E,IGNATOVA D,CHANG YT,et al.Expression of CD164 on malignant T cells in S¨¦zary syndrome £ÛJ£Ý.Acta Dermato-venereologica,2016,96(4):464-467.
£Û24£Ý CHEN JH,CHEN WL,CHAN JYH,et al.Overexpression of CD164 in oral cavity squamous cell carcinoma predicts a favourable prognosis £ÛJ£Ý.Oncology Letters,2017,14(5):6103-6108.
£Û25£Ý LIU JJ,XU ZM,LIU Y,et al.A novel lysosome-related prognostic signature associated with prognosis and immune infiltration landscape in oral squamous cell carcinoma £ÛJ£Ý.Heliyon,2024,10(4):e07964-e07979.
£Û26£Ý GONG Y,JOHNSSON AK,S¦FFHOLM J,et al.An optimized method for IgE-mediated degranulation of human lung mast cells £ÛJ£Ý.Frontiers in Immunology,2024,15:1393802-1393815.
£Û27£Ý WOLANCZYK-MEDRALA A,BARG W,LIEBHART J,et al.Validation of basophil CD164 upregulation for pollen allergy diagnosis £ÛJ£Ý.Archivum Immunologiae et Therapiae Experimentalis,2010,58:459-465.
£Û28£Ý WOLANCZYK-MEDRALA A,BARG W,MEDRALA W,et al.CD164 as a basophil activation marker £ÛJ£Ý.Current Pharmaceutical Design,2011,17(34):3786-3796.
£Û29£Ý BAKKERS MJ,MOON-WALKER A,HERLO R,et al.CD164 is a host factor for lymphocytic choriomeningitis virus entry £ÛJ£Ý.Proceedings of the National Academy of Sciences,2022,119(10):e2119676119-e2119676130.
£Û30£Ý LIU J,KNOPP KA,RACKAITYTE E,et al.Genome-wide knockout screen identifies human sialomucin CD164 as an essential entry factor for lymphocytic choriomeningitis virus £ÛJ£Ý.MBio,2022,13(3):e00205-22-e00205-40.
£Û31£Ý HIGHAM A,SCOTT T,LI J,et al.Effects of corticosteroids on COPD lung macrophage phenotype and function £ÛJ£Ý.Clinical Science,2020,134(7):751-763.
£Û32£Ý CHEN Y,LIU X,ZHANG L,et al.Deciphering the molecular characteristics of human idiopathic nonobstructive azoospermia from the perspective of germ cells £ÛJ£Ý.Advanced Science,2023,10(17):2206852- 2206867.
£Û33£Ý NYEGAARD M,RENDTORFF ND,NIELSEN MS,et al.A novel locus harbouring a functional CD164 nonsense mutation identified in a large Danish family with nonsyndromic hearing impairment £ÛJ£Ý.PLoS Genetics,2015,11(7):e1005386- e1005398.
£Û34£Ý WATT SM,B¦aHRING HJ,SIMMONS PJ,et al.The stem cell revolution:on the role of CD164 as a human stem cell marker £ÛJ£Ý.NPJ Regenerative Medicine,2021,6(1):33-47.
£Û35£Ý BENOIT BM,JARIWALA N,CONNOR G,et al.CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in S¨¦zary syndrome:the S¨¦zary signature genes,FCRL3,Tox,and miR-214 £ÛJ£Ý.Archives of Dermatological Research,2017,309:11-19.
£Û36£Ý SKYTTHE MK,GRAVERSEN JH,MOESTRUP SK,et al.Targeting of CD163+ macrophages in inflammatory and malignant diseases £ÛJ£Ý.International Journal of Molecular Sciences,2020,21(15):5497-5512.
£Û37£Ý VERMA M,TAMBOLI T,CHOUHAN M,et al.MicroRNA signature as biomarkers and therapeutic target for CNS embryonal tumors:The pros and the cons £ÛJ£Ý.International Journal of Pharmacy & Life Sciences,2022,13(11):1097-1110.
£Û38£Ý SHALABY T,FIASCHETTI G,BAUMGARTNER M,et al.MicroRNA signatures as biomarkers and therapeutic target for CNS embryonal tumors:the pros and the cons £ÛJ£Ý.International Journal of Molecular Sciences,2014,15(11):21554-21586.
£Û39£Ý OUMESLAKHT L,AZIZ AI,BENSUSSAN A,et al.CD160 receptor in CLL:current state and future avenues £ÛJ£Ý.Frontiers in Immunology,2022,13:1028013-1028025. £¨±àУ:̸¾²£©

Memo

Memo:

National Natural Science Foundation of China(No.81273174£©£»¹ú¼Ò×ÔÈ»¿Æѧ»ù½ð£¨±àºÅ£º81273174£©£»¹ú¼ÒÖصãÑз¢¼Æ»®¿ÎÌâ-¾«×¼Ò½Ñ§Ñо¿(±àºÅ£º2017YFC-0907404)£»ºÚÁú½­Ê¡×ÔÈ»¿Æѧ»ù½ðÖصãÏîÄ¿£¨±àºÅ£ºZD2022H006£©£»ºÚÁú½­Ê¡Ê¡Êô¸ßµÈѧУ»ù±¾¿ÆÑÐÒµÎñ·Ñ(±àºÅ£º2022-KYYWF-0651)£»¼Ñľ˹´óѧʡÖصãʵÑéÊÒ¿ª·Å¿ÎÌâ(±àºÅ£ºTFYJ202301)

Common functions

Last Update: 1900-01-01